New England Compounding Center Recalls Glycerin 100% Vials for Sterility Concerns
New England Compounding Center is recalling 165 vials of Glycerin 100% PF due to a lack of assurance of sterility. The product was distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric, particularly given the risk of infection associated with non-sterile medical products.
Plain-English summary
New England Compounding Center, located in Framingham, MA, is recalling 165 vials of Glycerin 100% PF in 1mL, 2 mL, and 5 mL sizes. The recall was initiated because the manufacturer could not ensure the sterility of the product.
The affected vials were distributed nationwide. The recall covers all lot codes for this specific product.
Consumers and healthcare providers should stop using the recalled vials and contact the manufacturer or their supplier for further instructions or a refund.
The recalled product
- Product
- Glycerin 100% PF, 1mL, 2 mL, and 5 mL vials, manufactured by New England Compounding Center, Framingham, MA
- Manufacturer
- New England Compounding Center
- Hazard
- Affected units
- 165
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lot codes
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 17 recalled by New England Compounding Center under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same manufacturer · New England Compounding Center
See all →- SevereNew England Compounding Center Recalls Lidocaine Vials Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- SevereNew England Compounding Center Recalls Isovue Vials Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- SevereNew England Compounding Center Recalls Lidocaine Dextrose Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- HighNew England Compounding Center Recalls Triamcinolone Vials Due to Sterility Concerns
FDA (Drugs) · 2013-01-09
- CriticalFDA Recalls Methylprednisolone Acetate Injection Due to Non-Sterility
FDA (Drugs) · 2013-01-09
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereSterile Products from New England Compounding Center Recalled Due to Sterility Concerns
FDA (Drugs) · 2012-11-21
- HighFDA Recalls Injectable Glycerin 72% Due to Sterility Assurance Failure
FDA (Drugs) · 2023-02-01
- HighInjectable Glycerin Sterile Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01
- SevereAdvanced Compounding Pharmacy Recalls Glycerin Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-06-03
- SevereProstaglandin Vials Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2019-04-24
- SevereAnderson Compounding Pharmacy Recalls HCG Vials Due to Sterility Concerns
FDA (Drugs) · 2019-04-24